Andra AP fonden Lowers Position in Zoetis Inc. $ZTS

Andra AP fonden cut its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 28.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 193,000 shares of the company's stock after selling 75,200 shares during the quarter. Andra AP fonden's holdings in Zoetis were worth $24,283,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of ZTS. Global Wealth Strategies & Associates purchased a new position in shares of Zoetis during the 4th quarter worth $25,000. Lodestone Wealth Management LLC purchased a new position in shares of Zoetis during the 4th quarter worth $30,000. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Zoetis during the 3rd quarter worth $31,000. Holos Integrated Wealth LLC purchased a new position in Zoetis during the 4th quarter valued at about $32,000. Finally, Elyxium Wealth LLC purchased a new position in Zoetis during the 4th quarter valued at about $32,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Weiss Ratings cut Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, March 27th. Stifel Nicolaus lowered their target price on Zoetis from $105.00 to $95.00 and set a "hold" rating for the company in a report on Friday, May 22nd. Wall Street Zen cut Zoetis from a "buy" rating to a "hold" rating in a report on Saturday, May 2nd. Argus restated a "hold" rating on shares of Zoetis in a report on Wednesday, May 27th. Finally, JPMorgan Chase & Co. lowered their target price on Zoetis from $190.00 to $130.00 and set an "overweight" rating for the company in a report on Friday, May 8th. Six equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $133.92.

Zoetis Stock Performance

Shares of ZTS opened at $81.51 on Friday. The stock has a 50-day simple moving average of $97.70 and a 200-day simple moving average of $114.47. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The stock has a market capitalization of $34.17 billion, a PE ratio of 13.52, a PEG ratio of 1.27 and a beta of 0.75. Zoetis Inc. has a 1 year low of $72.38 and a 1 year high of $168.83.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, analysts predict that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.6%. Zoetis's payout ratio is presently 35.16%.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Rosen, Bronstein Gewirtz & Grossman, the Schall Law Firm, DJS Law Group, and others, urged investors to join or lead a class action against Zoetis, keeping litigation risk in focus and potentially weighing on sentiment. Article Title
• Negative Sentiment: The lawsuits allege Zoetis misled investors about weakening veterinarian adoption and prescription trends, which could raise concerns about the company’s underlying growth outlook and create overhang on the stock. Article Title
• Neutral Sentiment: Rosen Law Firm and others reminded shareholders that July 27, 2026 is the lead-plaintiff deadline, but these notices are procedural and do not change Zoetis’ fundamentals by themselves. Article Title
• Neutral Sentiment: Bank of America Securities reportedly maintained a “Hold” rating on Zoetis, which suggests Wall Street remains cautious but not overtly bearish. Article Title

Insider Buying and Selling

In other news, Director Michael B. Mccallister purchased 3,000 shares of the business's stock in a transaction on Monday, May 11th. The shares were bought at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Paul Bisaro purchased 2,000 shares of the business's stock in a transaction on Wednesday, May 13th. The shares were purchased at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the transaction, the director owned 27,862 shares of the company's stock, valued at $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 11,650 shares of company stock worth $886,384 over the last 90 days. 0.22% of the stock is owned by insiders.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.